When osimertinib stops working: retesting and the next treatment

First establish what has changed

A scan report should be interpreted with symptoms, previous imaging and the overall response. Progression in one lesion, new brain disease and growth across several organs are different clinical situations. Ask the oncologist to show the pattern and explain how certain the finding is.

If symptoms are deteriorating, timely treatment takes priority while the assessment proceeds. Do not stop osimertinib independently while waiting for another opinion. The current team should explain whether to continue it during testing and how the next treatment will be timed.

Sources and references: [1] [2]

Limited progression may allow a focused intervention

For selected patients whose disease remains controlled in most places, surgery or radiation to a small number of progressing sites may be considered. The decision depends on the location, pace of growth and the feasibility of safely treating those sites.

Ask what continuing the current systemic drug is expected to achieve and when it will be reassessed. A local approach should have a clear follow-up plan. It is less likely to answer the problem when several organs are progressing at the same time.

Sources and references: [1]

Use retesting to answer a treatment question

Cancer can develop resistance through changes in EGFR or activation of another growth pathway. Blood-based sequencing can be useful, and tissue may provide additional molecular information. If blood testing is negative, it may reflect limited tumor DNA in the sample rather than an absence of resistance mechanisms.

Before a procedure, ask which findings would change the next treatment and whether existing tissue is informative enough. A new biopsy is particularly useful when the clinical course raises concern that the cancer's histology has changed, something mutation testing alone may not establish.

Sources and references: [2] [3] [4]

MET amplification creates a specific combination question

Acquired MET amplification can provide an alternative growth route despite EGFR inhibition. It is different from MET exon 14 skipping. The test method and degree of amplification need specialist interpretation before a MET-directed treatment is chosen.

In China, savolitinib with osimertinib is approved for locally advanced or metastatic EGFR-mutated nonsquamous NSCLC with MET amplification after progression on an EGFR inhibitor. This is a defined biomarker-selected use. MET protein overexpression and newly diagnosed disease involve separate evidence and should be evaluated under their own current indications or trials.

Sources and references: [5]

When a biomarker-selected combination is not the answer

Platinum-pemetrexed-based treatment remains an important option after EGFR-targeted therapy. In the United States, amivantamab with carboplatin and pemetrexed has an approved use after EGFR-TKI progression for exon 19 deletion or L858R disease. The choice also depends on treatments already received.

Datopotamab deruxtecan has a US accelerated approval after prior EGFR-directed therapy and platinum chemotherapy. Its place is therefore later than simply having one scan change on osimertinib. Ask the specialist to map alternatives onto your actual treatment sequence and the local prescribing framework.

Sources and references: [6] [7] [1]

A change in cancer type changes the plan

Some EGFR-mutated cancers develop a different histological pattern, including small cell transformation. A tissue biopsy can help identify this when suspected. The treatment then needs to address the new pathology rather than treating every progression as the same molecular problem.

Bring earlier pathology and the new specimen report to the review. Ask whether the findings explain an unusually rapid change or a response pattern that no longer fits the original disease. A joint pathology and oncology discussion can clarify whether the proposed regimen follows the revised diagnosis.

Sources and references: [1] [8]

Compare safety and trial timing before switching

A two-drug targeted regimen adds monitoring and interaction questions. ADCs can bring lung inflammation, mouth or eye problems, and other treatment-specific effects. Chemotherapy has its own blood-count and organ-function requirements. Review residual side effects from osimertinib before the next treatment begins.

If a trial is being considered, ask whether it requires a particular resistance result, a fresh biopsy or time off treatment. The oncologist should judge whether screening can fit safely into the disease timeline. Avoid creating a treatment gap while records and appointments are being arranged.

Sources and references: [2] [7] [9]

Build the Shanghai review around the resistance question

EastMedGo can help organize an inquiry about progression after osimertinib using baseline and recent scans, the original EGFR result, repeat testing and treatment dates. The pathology and molecular-review page explains the relevant assessment category.

Tell us whether the main question is a MET finding, a new biopsy, brain progression or a next-line regimen. We can help clarify the receiving team's requirements and coordination costs. Keeping the existing oncologist involved helps the review lead to a treatment decision without interrupting necessary care.

Common questions